

IN THE MATTER OF

\*

BEFORE THE

PAMELA KARNBACH, R.Ph.

\*

MARYLAND BOARD

LICENSE NO. 13350

\*

OF PHARMACY

\*

Case No. 18-151

\* \* \* \* \*

**ORDER STAYING SUMMARY SUSPENSION**

**Background**

Based on information received and a subsequent investigation by the Maryland Board of Pharmacy (the “Board”), and subject to the Maryland Pharmacy Act (the “Act”), Md. Code Ann., Health Occ. §§ 12-101, *et seq.*, and the Maryland Administrative Procedure Act, Md. Code Ann., State Gov’t. §§ 10-201 *et seq.*, the Board issued an Order for Summary Suspension dated June 20, 2018, in which it summarily suspended the pharmacist’s license held by Pamela Karnbach, R.Ph. (the “Respondent”). Specifically, the Board found reliable evidence demonstrated that the public health, safety or welfare imperatively required emergency action, pursuant to Md. Code Ann., State Gov’t §10-226(c)(2).

On September 12, 2018, the Board held a hearing before a quorum of the Board to allow the Respondent the opportunity to show cause why the Respondent did not pose an imminent threat to the health, safety and welfare of the public. Based on representations made by Respondent’s counsel at the show cause hearing regarding the Respondent’s recent drug screenings, and in accordance with COMAR 10.34.01.12G(2)(d), the Board is staying the summary suspension of the Respondent’s license pursuant to the terms contained herein.

**ORDER**

It is this 17<sup>th</sup> day of September, 2018, by an affirmative vote of the Maryland Board of Pharmacy, hereby:

**ORDERED** that the Order of Summary Suspension, dated June 20, 2018, be STAYED;  
and be it further,

**ORDERED** that the Respondent shall undergo monthly drug screenings through the submission of hair samples, at the direction of the Board or the Board's designated rehabilitation committee for at least one (1) year, or unless the Board issues a subsequent superseding order;  
and be it further

**ORDERED** that all drug screens under this Order shall be:

- 1) Submitted by the Respondent within 24 hours of the Board staff instructing her to submit a hair sample;
- 2) Submitted at a CLIA-certified laboratory; and
- 3) Negative for any controlled dangerous substance, narcotics, cocaine, or other mood-altering substance, except as provided below; and be it further,

**ORDERED** that the Respondent shall abstain from the ingestion of controlled dangerous substances, narcotics, cocaine, or other mood-altering substances, except that the Respondent may only ingest prescribed controlled dangerous substances for legitimate medical reasons under the following conditions:

- 1) The Respondent must be a bona fide patient of a licensed Maryland prescriber;
- 2) The medication must be lawfully prescribed by the Respondent's physician or other authorized medical practitioner;
- 3) The Respondent must provide the Board, in writing, within seventy-two (72) hours of receiving the medication: (a) the name and address of the prescriber; (b) the illness or medical condition diagnosed; (c) the type, strength, amount and dosage of the medication; (d) and a signed statement consenting to the release of all medical

information about the Respondent from the prescriber to the Board; and be it further,

**ORDERED** that in the event that the Respondent fails to timely submit to a drug screen, or the results of a drug screen are positive and without medical justification as set forth above, the Board may lift the stay of the summary suspension, provided that the Respondent has the opportunity for a hearing within a reasonable time thereafter, and be it further,

**ORDERED** that the Respondent shall at all times cooperate with the Board in the monitoring, supervision, and investigation of the Respondent's compliance with the terms and conditions of this Order; and be it further,

**ORDERED** that the Respondent shall bear the expenses associated with this Order; and be it further,

**ORDERED** that this Order shall not have any effect on the Board's discretion and authority to pursue formal disciplinary action against the Respondent's license in accordance with the Maryland Pharmacy Act; and be it further,

**ORDERED** that this document constitutes a formal order of the Maryland Board of Pharmacy and is therefore a public document, pursuant to the Public Information Act., General Provisions Art. § 4-333 and COMAR 10.34.01.12G(3).

9-17-18

Date

Deena Speights-Napata

Deena Speights-Napata, Executive Director  
for Jennifer Hardesty, Pharm.D.  
Treasurer, Maryland Board of Pharmacy

**NOTICE**

. Under the Board regulations, COMAR 10.34.01.12, you have the right to request a full evidentiary hearing before the Board on this matter. Any request for a hearing shall be made to the Board at the above address, attention Lisa Sanderoff, R.Ph., with a copy sent to the Administrative Prosecutor, Sherrai V. Hamm. The hearing will be held in accordance with the Maryland Administrative Procedure Act and the Board's regulations, COMAR 10.34.01.